Fund Holdings — ARCH Venture Management, LLC

Total Portfolio Value
$266.02M
Total Bought
$215.33M
Total Sold
$9.78M
Net Transaction
+$205.55M
Filing Period:
Securities
▲▼
SharesValue ($K)
Q1 2024
▲▼
Q2 2024
▲▼
Change
▲▼
Q1 2024
▲▼
Q2 2024
▲▼
Weight (%)
▲▼
Change
▲▼
BEAM THERAPEUTICS INC.(BEAM)05,443,039+5,443,0390127,53047.94%+127,530
RAPPORT THERAPEUTICS, INC.(RAPP)03,728,738+3,728,738086,73032.60%+86,730
ERASCA, INC.(ERAS)11,055,55411,055,554022,77426,0919.81%+3,317
SINGULAR GENOMICS SYSTEMS, INC.0126,630+126,63001,0700.40%+1,070
Q32 BIO INC.(FIXX)320,482320,48205,4615,7532.16%+292
UNITY BIOTECHNOLOGY, INC.1,004,8171,004,81701,6481,3570.51%-291
SINGULAR GENOMICS SYSTEMS, INC.3,798,9260-3,798,9261,9530—-1,953
GOSSAMER BIO, INC.(GOSS)8,055,9168,055,91609,5067,2582.73%-2,248
CERO THERAPEUTICS HOLDINGS, INC.(CERO)1,444,2961,444,29604,4344320.16%-4,002
DENALI THERAPEUTICS, INC.(DNLI)381,2490-381,2497,8230—-7,823
VERVE THERAPEUTICS, INC.2,008,8092,008,809026,6779,8033.69%-16,874
Page 1 of 1
ARCH Venture Management, LLC — 13F Holdings — Q2 2024 | TickerTrail